Spyre Therapeutics Unveils Promising IBD Therapies at UEGW Congress
Spyre Therapeutics, Inc. is set to make waves at the United European Gastroenterology Week (UEGW) Congress with a series of scientific presentations. The company will unveil promising preclinical data and Phase 1 study results for its innovative IBD therapies.
At the congress, Spyre will showcase new preclinical data demonstrating the superior efficacy of its combination programs. These include the dual inhibition of α4β7 and TL1A, α4β7 and IL-23, and TL1A and IL-23 in rodent models of TNBS-induced colitis. These combinations outperformed their individual components, indicating a potential breakthrough in IBD treatment.
In addition, Spyre will share follow-up data from its Phase 1 study of SPY002, a novel anti-TL1A agent for IBD. The results show that SPY002 was well-tolerated, with a distinct pharmacokinetic profile that supports quarterly or twice-yearly dosing. This could significantly improve patient convenience and adherence to treatment regimens.
Spyre Therapeutics is a clinical-stage biotech company specialising in next-generation IBD and other immune-mediated disease products. It combines best-in-class antibody engineering, dose optimisation, and rational therapeutic combinations to develop its innovative pipeline.
Spyre's poster presentations at the UEGW Congress will be available for viewing throughout the event, offering attendees a closer look at the company's groundbreaking research. With its promising preclinical data and Phase 1 study results, Spyre Therapeutics is poised to make a significant impact on the IBD treatment landscape.
